Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
about
Pathogenesis of the metabolic syndrome: insights from monogenic disordersDevelopment of an economic evaluation of diagnostic strategies: the case of monogenic diabetesPrevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.Precision diabetes: learning from monogenic diabetes.A Practical Review of C-Peptide Testing in DiabetesHigh-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes.Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetesLower Frequency of HLA-DRB1 Type 1 Diabetes Risk Alleles in Pediatric Patients with MODY.Adolescent non-adherence reveals a genetic cause for diabetesIdentifying monogenic diabetes in a pediatric cohort with presumed type 1 diabetes.Mutations in HNF1A result in marked alterations of plasma glycan profilePost-glucose-load urinary C-peptide and glucose concentration obtained during OGTT do not affect oral minimal model-based plasma indicesType 1 Diabetes Genetic Risk Score: A Novel Tool to Discriminate Monogenic and Type 1 DiabetesThe clinical utility of C-peptide measurement in the care of patients with diabetesSystematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cellsCost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic.Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetranceMost people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors.Clinical utility gene card for: Maturity-onset diabetes of the young.Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia.The effect of insulin resistance on postprandial triglycerides in Korean type 2 diabetic patients.Use of oral antidiabetic drugs in the treatment of maturity-onset diabetes of the young: A mini review.Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes.Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry.Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes.Who should have genetic testing for maturity-onset diabetes of the young?Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function.The spectrum of HNF1A gene mutations in Greek patients with MODY3: relative frequency and identification of seven novel germline mutations.C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase.Type 1 Diabetes in a Resource-Poor Setting: Malnutrition Related, Malnutrition Modified, or Just Diabetes?Tests aiding diagnosis of monogenic diabetes
P2860
Q27024024-9D710EF2-2971-4BC0-BC3E-F292FF940076Q28689671-5935168F-AC7D-426D-9545-7E4DD0EC1002Q30548217-D0117778-04F3-4FCF-9922-79ED25200646Q33453490-EE34A647-BFB1-4F8E-A5B4-5F6AF4F59281Q33732640-73558351-7B55-465D-B0FB-BF46352B14F6Q35123336-84C3CA4D-391B-4A45-8133-D3FFC9A332AEQ35894994-75A8342E-68A5-4CFD-84BE-3E8F8F2EB938Q35976364-28A5DB6F-B538-40D7-AE94-57457AFE78E1Q36157483-30A6A9D4-4431-4B78-8DAD-BF1CECA43C78Q36239494-3B5BB6BD-29F7-4BDB-A1AD-205AC2F944C1Q36268347-C8C28B74-DE6C-4B5A-B6FE-951AF779913AQ36618013-8AA8517A-693A-4A03-A40C-A814DB90F5DAQ36720490-6CD99443-1C01-49AC-9979-DE12CCC4C76FQ36778119-8AC4DABF-CEB2-44AF-AD93-220558CADDC6Q37036350-FC009918-3A6B-4E57-A78D-6118A1D02348Q37108880-E8297163-449F-4D83-87FA-7D571426B986Q37246676-827ECCD5-96BA-4150-9370-AB3E721A4B4BQ37374229-0ACBF2F6-1F0B-4CCE-81A4-0D96E95DA835Q37403160-BB9D9849-9354-457A-9173-7F7930A9C08CQ41251582-7EA0765B-34F6-46A8-81F9-9DD43C4631CCQ41513696-7BDE4736-D51D-4EDD-9180-96D498D8B9CCQ42376064-2FB47741-C0AA-40F1-B4FC-F4FF60AC44E0Q42380027-07B4D877-62BD-4181-8AF2-BA0D3087CBA4Q42796379-C524B0D9-0A85-473A-929F-46687BB6BAF9Q43805190-AF543563-6FDA-4286-B1F4-0A5B116CDA42Q45013586-B40073BF-DFC8-416D-A5A3-E6D7BED8E8EFQ48176468-80101ABF-F708-4345-94E2-3BEA3FAC3F34Q51280338-42421DD4-425E-4870-888C-0FB5900EDB3FQ51287966-9DC0923F-C9EE-47BB-A0E4-B696A0BBE04CQ51368838-57BB4CA6-63CF-4561-B633-F144AE3C4DD1Q51869413-EE054358-D1AD-43F9-8166-F6B4C3B527C2Q52874770-3755179E-A1F5-450C-A326-7707DAF5AC9BQ54267275-DC97EC96-4CAE-4664-A914-ED2463C6BFA5Q55422993-DDBA0946-D89C-495A-9ED4-1D9A4C3BC849Q55471387-EE13ECD7-2221-4D11-8C26-629F1D300562Q57917247-F0131BD0-1795-4585-A6E8-DED321FD41C6
P2860
Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@ast
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@en
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@nl
type
label
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@ast
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@en
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@nl
prefLabel
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@ast
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@en
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@nl
P2093
P2860
P50
P356
P1433
P1476
Urinary C-peptide creatinine r ...... long-duration type 1 diabetes.
@en
P2093
Beverley M Shields
Bridget A Knight
Maggie H Shepherd
Rachel E J Besser
P2860
P304
P356
10.2337/DC10-1293
P407
P577
2011-02-01T00:00:00Z